

Improving Women's Health



Who we are





Fempharma

is a research-driven B2B pharmaceutical company dedicated to serve the health of women with products that are based on innovation and state-of-the-art science.



Founded

in 2016 to fill unmet therapeutic gaps in the field of gynecology and urology.



International partnership

has started in 2020 to pave the road for our products to become available in 19 countries



Highest quality

is ensured by a certified ISO 13485 quality management system and a certified ISO 22000 food safety management system.



Intellectual property

many of our products are protected by international patents.





What we do





We out-license

our innovative dietary supplements and medical devices for distributors around the world who are involved in the sales and marketing of women's health products.



We prove the efficacy and safety

of our product through state-of-the-art clinical studies. In collaboration with research universities, we published over 25 scientific papers covering our products.



We protect

the intellectual property behind our products. In cooperation with a renowned law firm in New York we have 4 patents protecting our products worldwide.



We make quality

products in partnership with contract manufacturers who we continuously audit. We have certificates of ISO 13485 QMS for medical devices and ISO 22000 for food safety of our dietary supplements.



We create

products that fulfill currently existing unmet needs such as postnatal regeneration, effective incontinence therapy without side effects or local therapy for recurrence of vulvovaginal candidiasis.



We serve

our partners, providing (1) exclusive partnership for specified territories, (2) all documentation for registration, (3) patents, clinical studies and certifications, (4) high quality medical support and product training, (5) customized packaging, (6) demo units and competitive prices.

Products at a glance





JUVIAGEL vaginal moisturizing gel is a natural yet effective vaginal moisturizing gel that takes a new approach to treating vaginal dryness.



MOMAID postpartum recovery dietary supplement aimed to improve the recovery of the over-exerted, loose, or even injured muscles of the pelvic floor and perineum after childbirth



INCOXIL dietary supplement for stronger pelvic floor muscles and less urinary incontinence symptoms.



New approach in vaginal dryness therapy







Problem

Genitourinary syndrome of menopause (GSM) encompasses the genital (dryness, burning, and irritation), sexual (lack of lubrication, discomfort or pain) and urinary (urgency, dysuria, and recurrent urinary tract infections) symptoms.



Solution

JUVIAGEL is a non-hormonal moisturizing gel intended for the restoration of vaginal wall/mucosa integrity and vaginal health. Numerous clinical studies have tested the effectiveness of its ingredients both in animal and human cultured cell experiments.



JUVIAGEL vaginal moisturizing gel





Clinical advantages

Hormone free

Clear and odorless with a pleasant silky touch

Restores the natural pH value of the vagina and its original bacterial flora.

Same osmolality as natural vaginal fluid

Naturally helps to clean the vagina

Only product to comply with all WHO regulations

Glycerin, fragrance and paraben free

Non-toxic, non-irritating, does not cause epithelial injury

Used by thousands of women since 2018 with no complaints

Zinc helps to restore the elastin and collagen development in ECM of the vagina.

Product lifecycle is managed under ISO13485

JUVIAGEL vaginal moisturizing gel





Patent

VAGINAL TISSUE REJUVENATION COMPOSITIONS AND METHODS (US Patent No: 9,375,450, 6-28-2016 and EU Patent No: EP 2734159).



Scientific clinical study

Clinical trial has proved that JUVIA significantly improves postmenopausal vulvovaginal symptoms of women with GSM.

J Menopausal Med. 2019 Apr;25(1):63-68. Zinc-containing Vaginal Moisturizer Gel Improves Postmenopausal Vulvovaginal Symptoms: A Pilot Study



Pharmaceutical form

Medical Device

Aluminum tube (44ml) with sterilized plastic applicator

Information leaflet for consumers

Carton box 40mm x 40mm x 160mm

World's first supplement to support postpartum recovery



MOMAID

PATENTED POSTPARTUM DIETARY SUPPLEMENT TO SUPPORT HEALTHY RECOVERY AFTER DELIVERY




Problem

Pregnancy and birth places increased stress on the pelvic floor leaving the muscles fatigued and weak causing incontinence and sexual disfunctions. Pelvic floor dysfunctions affect about a quarter of the population in the developed world.



Solution

MOMAID contains a unique combination of Zinc, Leucine and Omega-3 fatty acids and directed at women after giving birth either through vaginal delivery or C-section to aid the restoration of muscular injuries.



MOMAID postpartum supplement





Clinical advantages

No other pharmaceutical treatment is currently known to help to repair the damaged muscles.

Scientifically proven efficacy

Chance of weak pelvic floor muscle strength decreased by 52%

Used by thousands of women since 2018 with no complaints

There are no side effects reported at recommended doses

Manufactured in a GMP complying factory, product lifecycle is managed under ISO22000

High patient satisfaction

MOMAID postpartum supplement





Patent

Pharmaceutical Composition for Postpartum Recovery and Treatment of Pelvic Floor Dysfunction (Publication Number: US-2021-0346427-A1; Publication Date: 11.11.2021).



Scientific clinical study

Randomized controlled trial for improved recovery of the pelvic floor after vaginal delivery with a specially formulated postpartum supplement.

Published on April 03, 2020 at Obstetrics & Gynecology Science 2020;63(3):305 314.



Pharmaceutical form

Dietary supplement Sachets 28 days

Soft gel capsule and tablets

Information leaflet for consumers

Carton box 90mm x 78mm x 120mm

Stronger pelvic floor muscles against urinary incontinence





PATENTED DIETARY SUPPLEMENT FOR STRONGER PELVIC FLOOR MUSCLES AND LESS URINARY INCONTINENCE



Problem

Urinary incontinence in women is a common problem. The most common form is stress incontinence (50%), followed by mixed stress-urge incontinence (40%). Incontinence is often difficult to treat.

Incontinence causes a major reduction in the quality of life for women of all age groups.



Solution

In order to increase the effectiveness of PFMT, we have developed a special dietary supplement INCOXIL with active ingredients of Creatine, Leucine, Calcium, Magnesium, and Zinc.

Pelvic floor muscle training (PFMT) is globally recommended as part of first-line treatment and is proven to work for all women with stress or mixed urinary incontinence.



INCOXIL incontinence supplement





Clinical advantages

No other proven pharmaceutical treatment is currently available for stress dominant UI.

Significantly greater strengthening in vaginal squeeze pressure

Greater improvement in the Biomechanical Integrity Score

Larger decrease in PGI-S score compared to control

Scientifically proven efficacy

There are no side effects reported at recommended doses

Manufactured in a GMP complying factory, product lifecycle is managed under ISO22000

INCOXIL incontinence supplement





Patent

US Patent Application was submitted "Pharmaceutical Composition and Method for Improving Biomechanical Integrity of the Pelvic Floor" APPLICATION NUMBER: 63438705



Scientific clinical study

A randomized controlled pilot trial to assess the effectiveness of a specially formulated food supplement and pelvic floor muscle training in women with stress-predominant urinary incontinence. BMC Women's Health 23, 321 (2023). https://doi.org/10.1186/s12905-023-02476-z.



Pharmaceutical form

Dietary supplement
Sachets 28 days
Instant drink powder
Information leaflet for consumers
Carton box 90mm x 78mm x 120mm

Alleviating the bothersome symptoms associated with the menstrual cycle





SPECIAL DIETARY SUPPLEMENT ADJUSTED TO THE PHASES OF THE MENSTRUAL CYCLE





Problem

Unpleasant symptoms associated with menstruation, also known as premenstrual syndrome (PMS) has been reported by 30-40% of the reproductive female population. With symptoms such as abdominal cramps, back pain, mood swings and fluid retention, PMS is one of the most difficult ailments women have to deal with and must do so on a consistent, monthly basis.



Solution

TRIPHASIN contributes to the specific vitamin and mineral demands of the female body according to the relevant phases and may soothe the unpleasant symptoms which may occur. It contains 3 different tablets with 3 different compositions, just as the menstrual cycle has three phases.

TRIPHASIN women cycle supplement





Clinical advantages

Based on rigorous health claims and published science

Three colored pills for easy use

Orange tablet contains higher amounts of iron and folic acid for follicular phase

Yellow tablet designed for ovulation phase, considered a transitional resting period

Green tablet designed to help to ease the symptoms of PMS containing Vitamin B1, B6, Vitamin D3,

Zinc and Magnesium

There are no side effects reported at recommended doses

Manufactured in a GMP complying factory, product lifecycle is managed under ISO22000

TRIPHASIN women cycle supplement





Scientific background (excerpt)

- Bull, JR et al. Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. npj Digital Medicine (2019) 2:83
- Nelson AL, Ritchie JJ. Severe anemia from heavy menstrual bleeding requires heightened attention. Am J Obstet Gynecol. 2015 Jul;213(1):97.e1-6. doi: 10.1016/j.ajog.2015.04.023.
- Fraser IS et al. Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey. Int J Gynaecol Obstet. 2015 Mar;128(3):196-200. doi: 10.1016/j.ijgo.2014.09.027. Epub 2014 Dec 1.



- Bahrami et al. High dose vitamin D supplementation can improve menstrual problems, dysmenorrhea, and premenstrual syndrome in adolescents. Gynecological Endocrinology 2018, VOL. 34, NO. 8, 659–663

Pharmaceutical form

Dietary supplement
Blister 28 days
Tablets in three colors
Information leaflet for consumers
Carton box 138 x 138 x 9mm

Pipeline - Vulvovaginal candidiasis





Vulvovaginal candidiasis

VVC is an exceedingly common mucosal infection of the lower female reproductive tract, caused mostly by the polymorphic opportunistic fungus Candida albicans. A member of the normal human microbiota, C. albicans commonly colonizes the vaginal lumen asymptomatically.



The PRA1 gene is expressed during vaginal infections, and this positively correlates with levels of proinflammatory cytokines in women. Genetic deletion of PRA1 prevented vaginal inflammation in mice and application of a zinc solution down-regulated expression of the gene and blocked immunopathology. Treatment of women suffering from recurrent vaginal candidiasis with a zinc gel prevented reinfections 1.

- © Currently, it's estimated that 75% of women will experience vulvovaginal candidiasis (VVC) in their lifetime.
- The fungus Candida albicans causes an estimated half billion vaginal candidiasis infections every year.
- The global vulvovaginal candidiasis treatment market size was valued at USD 986.5 million in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 4.39%.

1. E. Roselletti, E. Pericolini, A. Nore, P. Takacs, B. Kozma, A. Sala, F. De Seta, M. Comar, J. Usher, G. D Brown, D. Wilson: Zinc prevents vaginal candidiasis by inhibiting expression of an inflammatory fungal protein Science Translational Medicine, 6 Dec 2023 Vol 15. Issue 725



New approach treating VVC - JUVIAGEL



A retrospective cohort study was performed with the enrolment of 10 women with a history of recurrent vaginal infections at the outpatient clinic of the Department of Obstetrics and Gynecology, University of Debrecen, Hungary.


Recurrent vaginal infection included recurrent bacterial vaginosis (RBV) and recurrent vulvovaginal candidiasis (RVVC). Enrolment criteria included the presence of RBV or RVVC and recurrent vaginal infection was defined as three or more vaginal infections in the last 12 months (ACOG Practice Bulletin).

Women were asked to use JUVIAGEL as prophylactic treatment for two consecutive weeks and, after that, twice per week. They were asked to return to the clinic if any symptoms of vaginal infection were present for evaluation. Patients underwent a detailed gynecological exam at enrolment and the follow-up visit.

After being treated with a prophylactic treatment with a commercially available zinc-containing vaginal gel JUVIAGEL, results showed 62% reduction in infection.¹

A patent application was filed for VVC treatment under the US patent entitled "PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING OR PREVENTING CANDIDIASIS" (Application number: 63456387)

^{1.} Kozma B, Sipos AG, Pázkozdy K, Takács P. Zinc-containing vaginal gel for the prevention of recurrent vaginal infections: a pilot trial. Poster presentation at the 2022 American Urogynecologic Society and International Urogynecological Association's 47th Annual Meeting. June 14-18, 2022. Austin, Texas.



Certificates





ISO 13485:2016



ISO 22000:2018



Contact us



In person @



CPHI Milan, October 8-10, 2024, Milan, Italy

STAND 6SU32, HALL 6

Online @

https://en.fempharma.hu

Phone: +36 209 509 835

E-mail: zoltan.kovacs@fempharma.hu